Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab + mitomycin C
- Development stage
- Phase 4
- Lead developer
- Genentech
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravesical, Intravenous, Ophthalmic, Topical
01
Overview
Ranibizumab + mitomycin C is a combination of two pharmaceutical agents used primarily in ophthalmology and oncology. Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) that binds to and inhibits all isoforms of vascular endothelial growth factor A (VEGF-A), thereby preventing abnormal blood vessel growth and leakage in the eye. It is mainly indicated for wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy[1][6]. Mitomycin C is an antitumor antibiotic that acts as an alkylating agent, producing DNA cross-links which inhibit DNA synthesis and cell replication, leading to cell death. It is used as adjunctive therapy in glaucoma surgery (trabeculectomy) to prevent scarring, as well as for various cancers including bladder cancer[2][4][8]. The combination has been studied experimentally for use in ocular surgeries such as trabeculectomy or filtration procedures where both anti-fibrotic (mitomycin C) and antiangiogenic (ranibizumab) effects may be beneficial[3][5].
- Other names
- mitomycinmitomycin-C
02
Targets
Beyond the preview
Go deeper on ranibizumab + mitomycin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab + mitomycin C.